<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746395</url>
  </required_header>
  <id_info>
    <org_study_id>07-096</org_study_id>
    <nct_id>NCT00746395</nct_id>
  </id_info>
  <brief_title>Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy</brief_title>
  <official_title>Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sucampo Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Alabama</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation is designed to compare lubiprostone and placebo for cleansing and
      propulsion in preparation for capsule endoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction of small bowel capsule endoscopy made available an unique technique for
      diagnostic evaluation of the gastrointestinal tract. After esophagogastroduodenoscopy and
      colonoscopy about 5% of bleeding cases remain unexplained and capsule endoscopy provides
      small bowel yield. Capsule endoscopy has special application for evaluation of inflammation
      bowel disease and other small bowel conditions. Several adjuncts are used to enhance the
      examination by improving cleansing preparation or propulsion. Metoclopramide, tegaserod,
      simethicone, erythromycin, phosphates and polyethylene glycol (PEG) colon cleansing agents
      have been tried and some show improved visualization or increased propulsion where more
      capsules reach to colonic cecum while still recording within the limits of its 8 hour
      battery. Recently, our group had an observational report of our experience showing that
      either full bowel cleansing preparation or prokinetics such as metoclopramide or tegaserod
      enhanced visualization and functioning capsule transit to the colon. Lubiprostone is a novel
      chloride channel activator that increases intestinal fluid secretion and motility. It is FDA
      approved and indicated for treatment of chronic idiopathic constipation.

      This investigation is designed to compare lubiprostone and placebo for cleansing and
      propulsion in preparation for capsule endoscopy. The FDA approved 24 mcg constipation dose
      was chosen because other medications used in similar single dose in our pilot studies appear
      effective.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Small Bowel Transit</measure>
    <time_frame>8 hours</time_frame>
    <description>Percent of subjects with capsule passage through small bowel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Small Bowel Transit</measure>
    <time_frame>Duration of the test - 8 hours</time_frame>
    <description>Small bowel transit time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>lubiprostone 24mcg single dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lubiprostone 24mcg single dose po prior to capsule endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sugar pill) - matched single dose po prior to capsule endoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
    <description>24 mcg oral administration</description>
    <arm_group_label>lubiprostone 24mcg single dose</arm_group_label>
    <other_name>Amitiza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

        Exclusion Criteria:

          -  Gi disorders, gi surgery, cardiac, renal, or hepatic insufficiency, severe diarrhea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JAck A DiPalma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Alabama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USA Pavilion at Infirmary West</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2008</study_first_submitted>
  <study_first_submitted_qc>September 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2008</study_first_posted>
  <results_first_submitted>August 15, 2013</results_first_submitted>
  <results_first_submitted_qc>November 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2017</results_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Alabama</investigator_affiliation>
    <investigator_full_name>Jack DiPalma</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>capsule</keyword>
  <keyword>endoscopy</keyword>
  <keyword>prokinetic</keyword>
  <keyword>lubiprostone</keyword>
  <keyword>Normal</keyword>
  <keyword>volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from a speciality clinic in Mobile, AL, USA between October 2007 and August 2008.</recruitment_details>
      <pre_assignment_details>45 participants recruited and screened, 1 excluded, 4 withdrew from study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lubiprostone 24mcg Single Dose</title>
          <description>lubiprostone 24mcg single dose po prior to capsule endoscopy</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Placebo (sugar pill) - matched single dose po prior to capsule endoscopy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lubiprostone 24mcg Single Dose</title>
          <description>lubiprostone 24mcg single dose po prior to capsule endoscopy</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Placebo (sugar pill) - matched single dose po prior to capsule endoscopy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.75" spread="13.15045"/>
                    <measurement group_id="B2" value="35.4" spread="10.86472"/>
                    <measurement group_id="B3" value="37.07" spread="2.36881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Small Bowel Transit</title>
        <description>Percent of subjects with capsule passage through small bowel</description>
        <time_frame>8 hours</time_frame>
        <population>Placebo 95%, lubiprostone 75%</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24mcg Single Dose</title>
            <description>lubiprostone 24mcg single dose po prior to capsule endoscopy</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo (sugar pill) - matched single dose po prior to capsule endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Small Bowel Transit</title>
          <description>Percent of subjects with capsule passage through small bowel</description>
          <population>Placebo 95%, lubiprostone 75%</population>
          <units>percentage of subjects with passage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Small Bowel Transit</title>
        <description>Small bowel transit time</description>
        <time_frame>Duration of the test - 8 hours</time_frame>
        <population>Patients without transit to cecum were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Lubiprostone 24mcg Single Dose</title>
            <description>lubiprostone 24mcg single dose po prior to capsule endoscopy</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo (sugar pill) - matched single dose po prior to capsule endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Small Bowel Transit</title>
          <description>Small bowel transit time</description>
          <population>Patients without transit to cecum were excluded</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.1" spread="68.0"/>
                    <measurement group_id="O2" value="218.9" spread="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>October 2007 to August 2008</time_frame>
      <desc>No serious adverse events during study duration</desc>
      <group_list>
        <group group_id="E1">
          <title>Lubiprostone 24mcg Single Dose</title>
          <description>lubiprostone 24mcg single dose po prior to capsule endoscopy</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo (sugar pill) - matched single dose po prior to capsule endoscopy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study participant enrollment met per protocol requirement.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jack A. DiPalma, M.D.</name_or_title>
      <organization>University of South Alabama</organization>
      <phone>251-660-5555</phone>
      <email>jdipalma@usouthal.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

